Genmab — Januar 2021

[Darvin]

Som Sollsen så smukt skrev - blot et link

[Bulder]

Så kan EU også nå at bidrage, når salget kommer op at køre i H2.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

Amivantamab ( chrysalis ) https://www.onclive.com/view/dr-sabari-on-the-updated-results-of-the-chrysalis-study-with-amivantamab-in-egfr-nsclc?utm_source=sfmc&utm_medium=email&utm_campaign=1-29-21_AST-20-OSD0982_OncLiveSS_ GLOBAL WCLC Conference Coverage eNL_Tagrisso_1&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[Doublo]

God formiddag...er faren for en bund længere nede drevet over for denne gang? hvad siger TA

[Doublo]

Øver mig i at huske forkortelserne men har ikke helt styr på hvad NBI betyder?

[Klarussen]

@Doublo: det eneste sikre her i livet er bedemanden og skattefar. Der er ingen 100% sikkerhed i aktiemarkedet, heller ikke bunden for Genmab-kursen. Synes dog fremtiden for Genmab ser fornuftig ud på længere sigt, men meget kan ske både for Genmab og aktiemarkedet generelt.

[Doublo]

Klarussen jeg efterlyser ikke garantier men tendenser, vi har før fået fine TA-link

[Doublo]

tak for link Pensionisten

[E_L]

Sabari was confident enough in amivantamab’s data to take a swipe at mobocertinib, saying the Takeda program matched up poorly on safety given Thursday’s results.

“The data, to me, that’s been publicly available does not look as good as the data for amivantamab, and unfortunately with their TKI you see a lot of wild-type EGFR inhibition tox[icity] like diarrhea and rash, which you don’t see as commonly with amivantamab,” Sabari said.

[E_L]

https://endpts.com/jj-pushes-new-amivantamab-data-for-nsclc-subset-trying-to-bolster-case-for-quick-fda-approval/

[Helge_LarsenPI-redaktør]

Genmab: HexaBody https://www.proinvestor.com/index.php?p=debat_1&postid=90339

[E_L]

BlackRock funds @ 7.3% https://ir.genmab.com/node/39786/html
https://ir.genmab.com/stock-information/major-shareholders#content

[E_L]

think it was 7.1% before?

[peter12]

According to this Vanguard own 9% but I don't think you can trust it https://www.morningstar.com/stocks/xcse/gmab/ownership

[Klarussen]

What Type Of Shareholders Make Up Genmab A/S' (CPH:GMAB) Share Registry?

The big shareholder groups in Genmab A/S ( CPH:GMAB ) have power over the company. Insiders often own a large chunk of...

(simplywall.st)

[Klarussen]

13/1 2021 Simply Wall St. Jeg ved ikke om deres tal er de nyeste? Hvor ofte mon Genmab selv opdaterer det?

[peter12]

Ifølge Genmabs egen side er det kun Artisan og Blackrock der har mere end 5%, så det er nok E L's tal der passer

[Klarussen]

Simply Wall Street: Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Hedge funds don't have many shares in Genmab. Our data shows that Artisan Partners Limited Partnership is the largest shareholder with 7.7% of shares outstanding. Baillie Gifford & Co. is the second largest shareholder owning 5.5% of common stock, and BlackRock, Inc. holds about 5.3% of the company stock. In addition, we found that Jan G. van

[Klarussen]

de Winkel, the CEO has 1.0% of the shares allocated to their name.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.